Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

Grzegorz S. Nowakowski, Tatyana Feldman, Lisa M Rimsza, Jason R. Westin, Thomas E. Witzig, Pier Luigi Zinzani

Research output: Contribution to journalReview article

Abstract

Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with similar clinical presentations. Methodology to personalize treatment choices is being increasingly employed in clinical trials, yielding favorable correlations with improved response rates and survival. In patients with diffuse large B-cell lymphoma (DLBCL), disease characteristics and outcomes may vary widely, underscoring the importance of patient classification through identification of sensitive prognostic features. The discovery of distinct DLBCL molecular subtypes based on cell of origin (COO) is redefining the prognosis and treatment of this heterogeneous cancer. Owing to significant molecular and clinical differences between activated B-cell-like (ABC)- and germinal center B-cell-like (GCB)-DLBCL subtypes, COO identification offers opportunities to optimize treatment selection. Widespread adoption of COO classification would greatly improve treatment and prognosis; however, limitations in interlaboratory concordance between immunohistochemistry techniques, cost, and availability of gene expression profiling tools undermine universal integration in the clinical setting. With advanced methodology to determine COO in a real-world clinical setting, therapies targeted to specific subtypes are under development. The focus here is to review applications of precision medicine exemplified by COO determination in DLBCL patients.

Original languageEnglish (US)
Article number48
JournalBlood Cancer Journal
Volume9
Issue number6
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Fingerprint

Precision Medicine
Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Therapeutics
Germinal Center
Gene Expression Profiling
Survival Rate
Immunohistochemistry
Clinical Trials
Costs and Cost Analysis
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. / Nowakowski, Grzegorz S.; Feldman, Tatyana; Rimsza, Lisa M; Westin, Jason R.; Witzig, Thomas E.; Zinzani, Pier Luigi.

In: Blood Cancer Journal, Vol. 9, No. 6, 48, 01.06.2019.

Research output: Contribution to journalReview article

Nowakowski, Grzegorz S. ; Feldman, Tatyana ; Rimsza, Lisa M ; Westin, Jason R. ; Witzig, Thomas E. ; Zinzani, Pier Luigi. / Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. In: Blood Cancer Journal. 2019 ; Vol. 9, No. 6.
@article{b33f161f65eb4205aaafa0ed7eec476b,
title = "Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma",
abstract = "Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with similar clinical presentations. Methodology to personalize treatment choices is being increasingly employed in clinical trials, yielding favorable correlations with improved response rates and survival. In patients with diffuse large B-cell lymphoma (DLBCL), disease characteristics and outcomes may vary widely, underscoring the importance of patient classification through identification of sensitive prognostic features. The discovery of distinct DLBCL molecular subtypes based on cell of origin (COO) is redefining the prognosis and treatment of this heterogeneous cancer. Owing to significant molecular and clinical differences between activated B-cell-like (ABC)- and germinal center B-cell-like (GCB)-DLBCL subtypes, COO identification offers opportunities to optimize treatment selection. Widespread adoption of COO classification would greatly improve treatment and prognosis; however, limitations in interlaboratory concordance between immunohistochemistry techniques, cost, and availability of gene expression profiling tools undermine universal integration in the clinical setting. With advanced methodology to determine COO in a real-world clinical setting, therapies targeted to specific subtypes are under development. The focus here is to review applications of precision medicine exemplified by COO determination in DLBCL patients.",
author = "Nowakowski, {Grzegorz S.} and Tatyana Feldman and Rimsza, {Lisa M} and Westin, {Jason R.} and Witzig, {Thomas E.} and Zinzani, {Pier Luigi}",
year = "2019",
month = "6",
day = "1",
doi = "10.1038/s41408-019-0208-6",
language = "English (US)",
volume = "9",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

AU - Nowakowski, Grzegorz S.

AU - Feldman, Tatyana

AU - Rimsza, Lisa M

AU - Westin, Jason R.

AU - Witzig, Thomas E.

AU - Zinzani, Pier Luigi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with similar clinical presentations. Methodology to personalize treatment choices is being increasingly employed in clinical trials, yielding favorable correlations with improved response rates and survival. In patients with diffuse large B-cell lymphoma (DLBCL), disease characteristics and outcomes may vary widely, underscoring the importance of patient classification through identification of sensitive prognostic features. The discovery of distinct DLBCL molecular subtypes based on cell of origin (COO) is redefining the prognosis and treatment of this heterogeneous cancer. Owing to significant molecular and clinical differences between activated B-cell-like (ABC)- and germinal center B-cell-like (GCB)-DLBCL subtypes, COO identification offers opportunities to optimize treatment selection. Widespread adoption of COO classification would greatly improve treatment and prognosis; however, limitations in interlaboratory concordance between immunohistochemistry techniques, cost, and availability of gene expression profiling tools undermine universal integration in the clinical setting. With advanced methodology to determine COO in a real-world clinical setting, therapies targeted to specific subtypes are under development. The focus here is to review applications of precision medicine exemplified by COO determination in DLBCL patients.

AB - Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with similar clinical presentations. Methodology to personalize treatment choices is being increasingly employed in clinical trials, yielding favorable correlations with improved response rates and survival. In patients with diffuse large B-cell lymphoma (DLBCL), disease characteristics and outcomes may vary widely, underscoring the importance of patient classification through identification of sensitive prognostic features. The discovery of distinct DLBCL molecular subtypes based on cell of origin (COO) is redefining the prognosis and treatment of this heterogeneous cancer. Owing to significant molecular and clinical differences between activated B-cell-like (ABC)- and germinal center B-cell-like (GCB)-DLBCL subtypes, COO identification offers opportunities to optimize treatment selection. Widespread adoption of COO classification would greatly improve treatment and prognosis; however, limitations in interlaboratory concordance between immunohistochemistry techniques, cost, and availability of gene expression profiling tools undermine universal integration in the clinical setting. With advanced methodology to determine COO in a real-world clinical setting, therapies targeted to specific subtypes are under development. The focus here is to review applications of precision medicine exemplified by COO determination in DLBCL patients.

UR - http://www.scopus.com/inward/record.url?scp=85065870345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065870345&partnerID=8YFLogxK

U2 - 10.1038/s41408-019-0208-6

DO - 10.1038/s41408-019-0208-6

M3 - Review article

VL - 9

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 6

M1 - 48

ER -